Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
TCRR.US
id: 610, Created by Stan Vick, Scout
TCRR M&A Deal with ADAP Case
What do I get by joining?
- You will get case updates and receive a payout in case of success
- If you would like to actively participate, you will be connected to the attorney
- No, you do not pay anything out of your pocket neither to us nor to attorney
- $TCRR and $ADAP announced an all-stock merger.
- TCR² Therapeutics stockholders will own ~25% of the combined company.
- $TCRR Investors suspect that pricing terms of the M&A deal with $ADAP are unfair.
On March 6, 2023, Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. (NASDAQ: TCRR), announced entry into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock transaction.
Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company.
Investors of $TCRR may have reasons to suspect that the pricing terms of the M&A transaction with $ADAP are unfair and that the Company BoD breached fiduciary duties to shareholders.
Alleged Offence
Mismanagement,
Financial Misrepresentation,
Fraud,
Malpractice,
Negligence,
Breach of Fiduciary duty,
Omissions
Suspected Party
Directors,
Management,
Investment Bank,
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
06 March 2023